Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.

Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L.

Clin Ther. 2012 May;34(5):1170-81. doi: 10.1016/j.clinthera.2012.02.010. Epub 2012 Apr 17.

PMID:
22512898
2.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
3.

Methylphenidate bioavailability from two extended-release formulations.

González MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJ, Hatch SJ.

Int J Clin Pharmacol Ther. 2002 Apr;40(4):175-84.

PMID:
11996212
4.

In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.

Wang Y, Lee L, Somma R, Thompson G, Bakhtiar R, Lee J, Rekhi GS, Lau H, Sedek G, Hossain M.

Biopharm Drug Dispos. 2004 Mar;25(2):91-8.

PMID:
14872557
5.
6.

Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule.

Rochdi M, González MA, Dirksen SJ.

Int J Clin Pharmacol Ther. 2004 May;42(5):285-92.

PMID:
15176652
7.
8.

Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.

Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, Kim K, Park JW, Yoon H, Lee J, Park MS, Park K.

Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.

PMID:
22129569
9.

Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.

Wright CW, Aikman MS, Werts E, Seabolt J, Haeusler JM.

Clin Ther. 2009 Nov;31(11):2722-34. doi: 10.1016/j.clinthera.2009.11.025.

PMID:
20110014
10.

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R.

Clin Pharmacokinet. 2003;42(4):393-401.

PMID:
12648029
11.
12.

Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers.

Schütz H, Fischer R, Grossmann M, Mazur D, Leis HJ, Ammer R.

Int J Clin Pharmacol Ther. 2009 Dec;47(12):761-9.

PMID:
19954715
13.

Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential.

Spencer TJ, Biederman J, Martin JM, Moorehead TM, Mirto T, Clarke A, Batchelder H, Faraone SV.

Postgrad Med. 2012 Jan;124(1):166-73. doi: 10.3810/pgm.2012.01.2529.

PMID:
22314126
14.

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.

Tuerck D, Wang Y, Maboudian M, Wang Y, Sedek G, Pommier F, Appel-Dingemanse S.

Int J Clin Pharmacol Ther. 2007 Dec;45(12):662-8.

PMID:
18184535
15.

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733. Epub 2011 Jul 25.

PMID:
21787126
16.
17.

Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.

Lavy E, Prise U, Soldani G, Neri D, Brandriss N, Bar Chaim A, Giorgi M.

Vet J. 2011 Sep;189(3):336-40. doi: 10.1016/j.tvjl.2010.07.007. Epub 2010 Aug 8.

PMID:
20696604
18.

Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.

Adjei A, Teuscher NS, Kupper RJ, Chang WW, Greenhill L, Newcorn JH, Connor DF, Wigal S.

J Child Adolesc Psychopharmacol. 2014 Dec;24(10):570-8. doi: 10.1089/cap.2013.0135.

19.

Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.

Chen L, Jiang X, Huang L, Lan K, Wang H, Hu L, Ren J, Li X, Zou Q.

Clin Ther. 2009 Oct;31(10):2242-8. doi: 10.1016/j.clinthera.2009.09.015.

PMID:
19922895
20.

Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.

Wigal SB, Gupta S, Heverin E, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):255-63. doi: 10.1089/cap.2010.0083.

PMID:
21663428

Supplemental Content

Support Center